Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has successfully completed a fully underwritten retail entitlement offer, raising approximately A$10.6 million, alongside a placement and entitlement offer totaling A$100.2 million. The offer, which had a 62% take-up rate by eligible shareholders, will finance the company’s advancement towards marketing approval for its late-stage clinical trial program, including a Phase III trial in lung cancer. Shares from this offer are expected to start trading on the ASX on June 27, 2024.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
